Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• The sigma-1 (σ1) receptor is a potential therapeutic target.
• Developing novel σ1 receptor ligands is crucial for understanding its biological roles and for drug discovery.

Purpose of the Study:

• To synthesize novel stereoisomeric 2,5-diazabicyclo[2.2.2]octanes.
• To evaluate their σ1 receptor affinity and antitumor activity.

Main Methods:

• Chiral-pool synthesis from aspartate derivatives.
• Dieckmann-analogous cyclization with Me3SiCl trapping.
• σ1 receptor binding assays using animal and human membrane preparations.
• Molecular dynamics simulations for ligand-receptor interaction analysis.
• In vitro antitumor assays on human tumor cell lines.

Main Results:

• Stereoisomeric 2,5-diazabicyclo[2.2.2]octanes were successfully synthesized.
• Compounds showed affinity for the σ1 receptor, with good correlation between experimental and calculated binding energies.
• Structure-affinity relationships were established, identifying key ligand-receptor interactions.
• Selective inhibition of A427 tumor cell growth was observed, mediated by apoptosis induction.
• Antitumor activity mimicked that of the σ1 receptor antagonist haloperidol.

Conclusions:

• The synthesized bicyclic compounds are potent σ1 receptor ligands.
• These compounds exhibit selective antitumor activity against A427 cells via apoptosis.
• The findings support the role of σ1 receptor modulation in cancer therapy.